| Tazemetostat (EPZ-6438) |
EPZ-6438 |
1403254-99-8 |
| BS-181 HCl |
BS181 |
1397219-81-6 |
| 1-Cyclopentyl-N-((4,6-diMethyl-2-oxo-1,2-dihydropyridin-3-yl)Methyl)-6-(4-(MorpholinoMethyl)phenyl)-1H-indazole-4-carboxaMide |
EPZ005687 |
1396772-26-1 |
| LY3023414 |
LY-3023414 |
1386874-06-1 |
| BRD4770 |
2-苯甲酰胺基-1-(3-苯丙基)-1H-苯并[D]咪唑-5-羧酸甲酯 |
1374601-40-7 |
| ON123300 |
8-环戊基-7,8-二氢-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-7-氧代-吡啶并[2,3-D]嘧啶-6-甲腈 |
1357470-29-1 |
| N-cyclohexyl-2-(N-(3-fluorophenyl)-2-(2-Methyl-1H-iMidazol-1-yl)acetaMido)-2-(o-tolyl)acetaMide |
AGI-5198 (IDH-C35) |
1355326-35-0 |
| EW-7197 |
EW-7197 |
1352608-82-2 |
| MK5172 |
格佐匹韦 |
1350514-68-9 |
| S)-1-(sec-butyl)-N-((4,6-diMethyl-2-oxo-1,2-dihydropyridin-3-yl)Methyl)-3-Methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxaMide |
GSK126 |
1346574-57-9 |
| INCB8761(PF-4136309) |
INCB8761(PF-4136309) |
1341224-83-6 |
| PI3K/HDAC Inhibitor |
CUDC-907 |
1339928-25-4 |
| N-(5-(1-(2,6-dichlorophenyl)-3-(difluoroMethyl)-1H-pyrazol-5-yl)thiazol-2-yl)cyclopropanecarboxaMide |
BMS-3 |
1338247-30-5 |
| azd4635 |
AZD4635 |
1321514-06-0 |
| ACY-1215 |
ACY1215 |
1316214-52-4 |
| GDC-0032 |
GDC 0032 |
1282512-48-4 |
| LY 2874455 |
LY2874455 |
1254473-64-7 |
| mi503 |
MI-503 |
1857417-13-0 |
| LRRK2-IN-1 |
5,11-二氢-2-[[2-甲氧基-4-[[4-(4-甲基-1-哌嗪基)-1-哌啶基]羰基]苯基]氨基]-5,11-二甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮杂卓-6-酮 |
1234480-84-2 |
| 3-Amino-6-[4-(methylsulfonyl)phenyl]-N-phenyl-2-pyrazinecarboxamide |
3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-吡嗪甲酰胺 |
1232410-49-9 |
